S. Amsaveni

S. Amsaveni

Auto-generated profile, based on publicly available information

S. Amsaveni

Department of Bioinformatics, School of Life Science, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Current Gene Therapy
Verified
Journal Article
Closed access
PDF file
SASivaprakasam S. Amsaveni
Sivaprakasam S. Amsaveni
MRMahendran Radha
Mahendran Radha
VCVidhya Chandrasekaran
Vidhya Chandrasekaran
DCDilip Kumar Chanchal
Dilip Kumar Chanchal
SMSojomon Mathew
Sojomon Mathew
SASyed Salman Ali
Syed Salman Ali
The immune system presents significant obstacles to gene therapy, which has limited its use in treating many illnesses. New approaches are needed to overcome these problems and improve the effectiveness of gene therapy. This study explores several techniques to immune regulation within gene therapy, a cutting-edge discipline that aims to optimise results by fine-tuning the immune response. We cover new ways to control the immune system and deliver therapeutic genes just where they are needed, including influencing immunological checkpoints, causing immunotolerance, and making smart use of immunomodulatory drugs. In addition, the study provides insight into new developments in the design of less immunogenic gene delivery vectors, which allow for the extension of transgene expression with minimal adverse immune reactions. In order to maximise the efficacy of gene-based therapies, this review analyses these novel approaches and gives a thorough overview of the present state of the art by addressing obstacles and pointing the way toward future developments in immune regulation. Not only does their integration provide new opportunities for the creation of safer and more effective gene treatments, but it also contains the key to overcome current obstacles.

23 October 2023 in Journal of Pure and Applied Microbiology
Verified
Journal Article
Open access
VAV. Anitharaj
V. Anitharaj
JPJ. Pradeep
J. Pradeep
SAS. Amsaveni
S. Amsaveni
SSSelvaraj Stephen
Selvaraj Stephen
PPPooja Pratheesh
Pooja Pratheesh
Scrub typhus (ST) is a re-emerging zoonotic disease caused by Orientia tsutsugamushi and is transmitted by chiggers. Serological tests targeting IgM and/or IgG antibodies play a major role in the detection of ST cases. Orientia 56kDa genome is common target for the molecular diagosis of ST to identify the prevalence of specific serotypes of O. tsutsugamushi in and around Puducherry by targeting 56kDa gene with the application of phylogenetic analysis. This prospective laboratory-based study was conducted in a tertiary care teaching hospital, from November 2105 to March 2018. Blood samples were collected from out-patients/in-patients, and those tested positive for ST IgM ELISA (n=140) and an equal number of negative samples were archived and anonymized. Genomic DNA was extracted and analyzed by using Nested PCR and LAMP assay. The positive products were purified and sequenced. Phylogenetic tree was constructed based on the sequences. Among 280 samples, 45 (16.1%) N-PCR and 102 LAMP (36.43%) positivity was observed for 56kDa gene. Forty-one N-PCR positive products were sequenced and accession numbers were obtained (MG601875 to MG601917) for the isolates. Phylogenetic analysis was done by Maximum Likelihood methods and this study has showed that 32.3% are similar to the Karp isolates. Molecular diagnosis of Scrub typhus has become essential in case of doubtful serology and early acute phase of illness. Gene sequencing result indicates that most of them were different from the existing ones, which may belong to the newer strains. The identification of newer strains will be helpful in future for development of scrub typhus vaccine.

27 October 2025 in Asian Journal of Chemistry
Verified
Journal Article
Open access
PDF file
GSG. Surya
G. Surya
SAS. Amsaveni
S. Amsaveni
MRMahendran Radha
Mahendran Radha
In this study, phytochemical analysis of Anisomeles malabarica (L.) led to the identification of 25 bioactive compounds. The presence of key secondary metabolites including flavonoids, alkaloids, terpenoids, tannins, steroids, anthraquinones and phenols was confirmed, highlighting the plant’s rich pharmacological profile. Among various extracts tested, the ethanol extract exhibited the most significant anti-inflammatory activity, suggesting its potential for further pharmacological and therapeutic exploration. The bioactive compounds that satisfied Lipinski's rule of five were isolated and subjected to further evaluation. Their physico-chemical properties, toxicity profiles, and drug-likeness were predicted using in silico ADMET analysis tools. Molecular docking studies demonstrated strong binding affinities of several compounds toward Interleukin-6 (IL-6), a key pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis, suggesting their potential as therapeutic agents for inflammatory disorders. When compared to control tofacitinib (-6.17 Kcal/mol), bioactive compounds such as dinaphthofuran (-9.48 Kcal/mol) and isoxazole[4,3-a]phenazine,1-phenyl (-9.07 Kcal/mol) have shown a substantial binding affinity to Interleukin-6, making them potentially useful for anti-inflammatory therapeutics. RBC membrane stabilization assays showed concentration-dependent protection against hypotonic-induced haemolysis, supporting the extract’s ability to prevent cellular damage and inflammation. Overall, A. malabarica leaf extracts demonstrated significant anti-inflammatory potential, with dinaphthofuran and isoxazolo[4,3-a]phenazine,1-phenyl identified as lead candidates for further drug development targeting rheumatoid arthritis.